tumor vasculature, 4 microvesicles, 5 bacteria, 6 and viruses, 7 expose unusually high levels of negatively charged phospholipids. Proteins and antibodies that can selectively target these anionic membrane surfaces and distinguish them from the near-neutral membrane surfaces of normal human cells have promising potential as imaging probes, 8 drug delivery agents, 9 and targeted molecular therapeutics. 10 Notable examples are the protein, Annexin V, which is under clinical investigation as an imaging probe for dead/dying tissue, 11 and the antibody, Bavituximab, which targets viruses and tumor vasculature. 12 It is often challenging to optimize the formulation and pharmaceutical properties of proteins; thus, there is a need to develop small molecule mimics of these proteins that exhibit the same targeting capabilities.
13
Synthetic zinc(II)-dipicolylamine (Zn-DPA) coordination complexes are known to associate with multianionic phosphorylated biomolecules, 14 and we have discovered that they can be converted into optical imaging probes that target the outer surfaces of anionic vesicle and cell membranes.
15 Fluorescent Zn-DPA probes can distinguish dead and dying mammalian cells from healthy cells in a cell culture 16 and also selectively target bacteria in heterogeneous biological media. 17 Furthermore, we have recently demonstrated that the near-IR fluorescent probe 1 can be used to image bacterial infections in living mice, 18 indicating that probe 1 has a notable ability to selectively target anionic cells over other anionic sites in the bloodstream and extracellular matrix. Here, we greatly expand the animal imaging capability of probe 1 by showing that it can also target the anionic dead and dying cells within xenograft tumors in rat and mouse models. The structure of probe 1 includes a near-IR carbocyanine fluorophore whose absorption and emission wavelengths of 794 and 810 nm, respectively, are within the optimal window for maximum penetration through skin and tissue. 19 The high tumor selectivity of 1 is demonstrated by comparison to the less-selective imaging that is achieved by using control near-IR fluorophores 2 and 3 whose structures do not have Zn-DPA targeting ligands. 20 The expected ability of probe 1 to selectively target dead and dying cells with exposed anionic phosphatidylserine was confirmed with in vitro fluorescence microscopy studies of mammalian cells treated with a cytotoxic agent. 16 Specifically, treatment of Jurkat cells (T lymphocytes) with camptothecin induced significant amounts of cell death, and as shown in Figure 1 , the near-IR probe 1 stained the same cells as fluorescently labeled Annexin V. Using procedures that were approved by the appropriate institutional animal care and use committee, two tumor bearing animal models were selected for in vivo imaging: (1) immunocompetent Lobund Wistar rats with PAIII prostate tumors 21 and (2) athymic nude mice containing EMT-6 mammary tumors. 22 These two tumor models were chosen, in part, because they develop foci of necrotic cells, especially in the tumor cores. A typical imaging study of the rat prostate tumor model employed three cohorts of rats with 1 × 10 6 PAIII cells injected subcutaneously in the right flank. The tumors grew over ∼14 days followed by intravenous injection of either probe 1, 2, or 3 (3.0 mg/kg). The rats were anesthetized and placed in a whole-body, small animal imaging station that was configured for epifluorescence imaging. 23 Each animal was illuminated with filtered light at 750 ( 10 nm, and the emission intensity was collected at 830 ( 20 nm. In addition, a coregistered X-ray image was acquired. Clearance of the probes from the bloodstreams of the living animals was monitored by imaging at regular 3-h intervals. In the case of probe 1, there was clear evidence for selective accumulation in the tumor after 24 h (Figure 2A) . A region of interest analysis compared the tumor signal intensity with the signal from the same area of skin on the opposite side of the rat, to give a target to nontarget ratio (T/NT). At the 24 h time point, the average T/NT for the cohort treated with probe 1 was 2.2 and about twice that for control fluorohores 2 and 3. The rats were then sacrificed, and their tissues harvested for ex vivo analysis of probe biodistribution. Fluorescence intensity images of the excised tissues confirmed the relatively high tumor selectivity of probe 1 (see Supporting Information). The bar graph in Figure 2B shows that average tumor targeting with probe 1 was 36-fold higher than control 2 and also much higher than control 3. 24 The spatial distribution of probe 1 within the resected tumors was determined by slicing them in half along the longest axis. Fluorescence imaging of the interior-facing surfaces of these tumor halves revealed that probe 1 was not distributed uniformly, with the highest fluorescence intensities coming from the core of the tumors ( Figure 3A) . Additional microscopic imaging of histological slices showed that the near-IR fluorescence from 1 colocalized with the tumor's necrotic regions (compare Figure 3B and 3C and see Supporting Information for additional histological analyses).
The ability of 1 to target and identify tumors in vivo was further tested using a mouse EMT-6 mammary tumor model. In a typical study, two cohorts of NCRNU nude mice were subcutaneously injected with 1 × 10 5 EMT-6 mammary carcinoma cells in the right shoulder. After 10 days, the tumors were palpable, and probe 1 or control 2 (3.0 mg/kg) was injected intravenously into the mice via the tail vein. As before, fluorescence imaging was used to monitor clearance of the probes from the bloodstreams of the living animals. The in vivo image in Figure 4 shows a typical tumor bearing mouse at 24 h postadministration of probe 1. The average T/NT ratio for the cohort treated with probe 1 was 70% greater than T/NT for control 2 (see Supporting Information). As with the rat prostate tumor model, ex vivo imaging of the excised mouse 1, 2, and 3 (B) . The values represent the mean (n ) 3), ( standard error of the mean. *P < 0.0005. These imaging data are representative of four replicate studies using independent cohorts. control 2 (B) . The values represent the mean (n ) 3), ( standard error of the mean. *P < 0.005. These imaging data are representative of three replicate studies using independent cohorts. tissues showed that average tumor selectivity for probe 1 was almost 18-fold higher than control 2. 24 Again, the tumors were sliced in half and fluorescence imaging showed that the probe localized toward the interior of the tumors. Confirmation that the tumor cores contained significant regions of dead/dying tissue was gained by TUNEL analysis of histological slices.
In summary, the synthetic fluorescent near-IR imaging probe 1 with an appended Zn-DPA affinity ligand can selectively accumulate in prostate and mammary tumors in two different xenograft animal models. Ex vivo biodistribution and histological analyses suggest that probe 1 targets the necrotic regions of the tumors, 25 which is consistent with in vitro microscopy showing selective targeting of the anionic membrane surfaces of dead and dying cells. Imaging probes that can determine, noninvasively, the amount and type of cell death in tumors may have utility in clinical prognosis of tumor pathogenesis.
26 Future studies will evaluate if probe 1 can be used to noninvasively monitor tumor cell death due to anticancer therapy. 27 It should also be possible to produce analogous Zn-DPA probes with reporter groups that allow deep tissue imaging of cancer in humans. 28 
